Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA".
Filed with NSE · ISIN INE010B01027 · · 4 pages · English
Zydus Lifesciences Limited on 6ix
Story so far
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 05, 2026, titled "Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.".
- Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada
Earlier from Zydus Lifesciences
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
- Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.
- Zydus Lifesciences Limited Press Release Sep 26 2026
- Zydus Lifesciences Limited Press Release Aug 31 2026
- Zydus Lifesciences Limited Press Release Aug 21 2026
Later from Zydus Lifesciences
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "USFDA inspection concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 15, 2026, titled "Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Zylidac Bio and Prolific Machines Partner to Scale Prolific s Next-Generation Biologics Manufacturing Platform to GMP Production".
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences